What Is Plaque in Arteries and Can It Be Reversed?

Arterial plaque is a waxy buildup of fats, cholesterol, immune cells, calcium, and other debris that accumulates inside the walls of your arteries over years or decades. Whether it can be reversed depends on what you mean by “reversed.” Full elimination of plaque back to a pristine artery is not something current medicine achieves, but meaningful shrinkage of plaque and, perhaps more importantly, stabilization of dangerous plaque into a less threatening form are both well-documented outcomes of aggressive treatment. The distinction between shrinking plaque and stabilizing it turns out to matter more than most people realize.

How Plaque Forms in the First Place

Plaque does not appear overnight. The process begins when low-density lipoprotein, the so-called “bad cholesterol,” slips into the inner lining of an artery wall and gets trapped there. Your immune system treats that trapped cholesterol as a problem and sends white blood cells called macrophages to clean it up. Those macrophages gorge on lipids and swell into what researchers call foam cells, which are essentially fat-stuffed immune cells stuck inside the artery wall.¹ This initial stage is known as a fatty streak, and it can begin as early as adolescence in some people.

Over time, more lipids accumulate, more immune cells pile in, and smooth muscle cells migrate into the area and start producing a fibrous cap over the growing deposit. What you end up with is a layered structure: a soft, lipid-rich core covered by a cap of fibrous tissue. Some plaques also develop calcium deposits, making them hard and rigid. The whole process is called atherosclerosis, and it progresses silently for years before causing any symptoms.

Why Some Plaques Are Dangerous and Others Are Not

Not all plaque is equally threatening. A large, calcified plaque that has been sitting in an artery wall for decades can narrow blood flow and cause symptoms like chest pain during exertion, but it may never cause a heart attack. The plaques that kill people tend to be the ones that rupture. Pathology studies going back three decades have shown that plaque rupture followed by a blood clot forming at the rupture site is the primary mechanism behind acute coronary syndrome and sudden cardiac death.²

The plaques most prone to rupture tend to share certain features: a large, soft lipid core, a thin fibrous cap, and active inflammation. Cardiologists sometimes call these “vulnerable” or “high-risk” plaques. They are often not the ones causing the most narrowing on an angiogram, which is part of what makes heart attacks so unpredictable. A person with a 40% blockage from a vulnerable plaque can be at greater immediate risk than someone with an 80% blockage from a stable, calcified plaque. This is why the conversation about reversing plaque is incomplete without talking about stabilization.

Stabilization vs. Shrinkage

When doctors and researchers talk about plaque “regression,” they are not describing a simple rewind of the buildup process. Regression involves several distinct biological changes happening at once: lipids and dead-cell debris get cleared out of the artery wall, the inflammatory cells that were driving the process quiet down, the fibrous cap covering the plaque thickens and strengthens, and in some cases the plaque becomes more calcified in a dense, stable pattern.³ The result is a plaque that is smaller, denser, and far less likely to rupture.

This matters because you could have a treatment that barely shrinks plaque volume but dramatically reduces your risk of a heart attack by converting soft, inflamed plaque into hard, stable plaque. Conversely, a treatment that chips away at plaque volume without stabilizing it would be less useful. In practice, the therapies with the best evidence tend to do both, but stabilization is the more immediate and clinically meaningful benefit. A thicker fibrous cap and a smaller lipid core mean a plaque that is much less likely to tear open and trigger a clot.

What Statins Actually Do to Plaque

Statins are the most studied drugs in the plaque-regression space, and the evidence is clear that high-intensity statin therapy can shrink arterial plaque, not just slow its growth. In one well-known imaging trial, patients who received high-intensity statin therapy after a heart attack had their coronary arteries examined with intravascular ultrasound at baseline and again after 13 months. Their LDL cholesterol dropped substantially, and the volume of plaque in their non-affected coronary arteries shrank by a small but statistically meaningful amount.⁴

The absolute amount of shrinkage measured in studies like this is modest. We are talking about less than one percentage point of plaque volume over roughly a year. That sounds tiny, but keep in mind that in untreated patients, plaque typically grows over the same period. Turning a growing deposit into a shrinking one is a meaningful shift in trajectory, especially when combined with the stabilization effects described above. The lower you push LDL cholesterol, the more regression you tend to see, which is why guidelines have moved toward more aggressive cholesterol-lowering targets over the past two decades.

Beyond Statins: Newer Cholesterol-Lowering Drugs

Because the relationship between LDL levels and plaque regression appears to follow a “lower is better” pattern, researchers have been interested in whether adding newer drugs on top of statins can push plaque regression further. One major line of investigation involves PCSK9 inhibitors, a class of injectable drugs that can cut LDL cholesterol dramatically when added to statin therapy. The GLAGOV trial was designed specifically to test whether the PCSK9 inhibitor evolocumab would produce greater plaque regression than statin therapy alone, using intravascular ultrasound to measure changes in coronary plaque volume.⁵

The concept behind these drugs is straightforward: PCSK9 is a protein that chews up the receptors your liver uses to pull LDL out of your bloodstream. Block PCSK9, and your liver clears LDL more efficiently, driving blood levels down to ranges that statins alone often cannot reach. For patients who are already on maximum-dose statins and still have elevated LDL, or who cannot tolerate statins at all, PCSK9 inhibitors offer an alternative path to very low cholesterol levels. The plaque-regression data from trials in this drug class have generally supported the idea that more LDL lowering means more regression, reinforcing the importance of cholesterol as the central driver of the process.

Can Lifestyle Changes Alone Reverse Plaque?

One of the most frequently asked follow-up questions is whether you can reverse plaque without drugs, through diet and exercise alone. The most cited evidence on this comes from Dean Ornish’s lifestyle intervention trial, which put patients with documented coronary artery disease on an intensive program involving a very low-fat vegetarian diet, moderate aerobic exercise, stress management, and group support. After one year, the intervention group showed a small improvement in the degree of artery narrowing, and after five years, the improvement had grown to about a 3 percentage-point reduction in the severity of their blockages.⁶ The comparison group, following usual care, got worse over the same period.

These results are genuine and meaningful, but they come with important caveats. The lifestyle program in that trial was intensive by any standard. Participants ate a diet with less than 10% of calories from fat, exercised regularly, practiced stress reduction daily, and attended group sessions. This is not the same as cutting back on fried food and walking a few times a week. Most people in real life do not sustain that level of commitment for five years, which is why the study’s results, while encouraging as proof of concept, are difficult to replicate at a population level.

That said, the finding is striking because it demonstrates that the biological machinery for plaque regression exists and can be activated without pharmaceutical intervention. The body can, under the right conditions, begin clearing lipids from artery walls and rebuilding the surrounding tissue. The practical question for most people is whether they can achieve enough LDL reduction through lifestyle changes alone or whether medication is needed to reach the threshold where regression kicks in.

How Doctors Monitor Plaque Today

If plaque regression is possible, you might wonder how your doctor would know whether it is happening. In research settings, the gold standard has been intravascular ultrasound, where a tiny probe is threaded into a coronary artery to directly measure plaque volume. This is invasive and not something done routinely for monitoring. In everyday clinical practice, doctors rely on indirect measures: your cholesterol numbers, blood pressure, inflammatory markers like C-reactive protein, and coronary calcium scores from CT scans.

Coronary calcium scoring deserves a special mention here because it confuses people in the context of plaque regression. A coronary calcium score measures how much calcified plaque you have in your coronary arteries. Counterintuitively, your calcium score can go up even as your overall cardiovascular risk goes down, because one of the ways plaque stabilizes is by calcifying. A soft, vulnerable plaque converting into a dense, calcified plaque is a good thing from a risk standpoint, but it can show up as a higher calcium score on a CT scan. This is one reason cardiologists generally do not recommend serial calcium scoring to track treatment response. The number can move in the “wrong” direction while the actual biology is moving in the right direction.

What “Reversal” Realistically Looks Like

Given everything above, the honest framing is that partial plaque regression is achievable with aggressive LDL lowering, whether through medication, intensive lifestyle changes, or a combination. The degree of regression documented in clinical trials is real but modest in absolute terms. You are not going to dissolve decades of buildup back to the arteries you had at age 20. What you can do is shrink the lipid core of existing plaques, thicken the protective cap over them, reduce inflammation in the artery wall, and shift the overall character of your plaque from dangerous to stable.

For most people with established atherosclerosis, the practical goal is to get LDL cholesterol low enough to tip the balance from plaque progression to plaque regression or at least stabilization. The threshold varies from person to person, but research consistently shows that lower LDL levels produce more regression. Current guidelines for people who have already had a cardiovascular event often target LDL levels below 70 mg/dL, and some evidence suggests that pushing below 50 mg/dL produces even more benefit. These targets would have seemed extreme two decades ago, but the imaging data on plaque regression have helped shift the field.

Common Misconceptions About Arterial Plaque

A widespread belief is that plaque is like the gunk clogging a pipe, sitting on the inner surface of the artery and waiting to be scraped or flushed away. In reality, plaque forms within the artery wall itself, between the inner lining and the muscular layer. You cannot scrub it out or dissolve it with a particular food or supplement, no matter what internet ads claim. Chelation therapy, garlic supplements, apple cider vinegar protocols, and various “artery cleanse” products have no credible evidence showing they reduce plaque volume.

Another misconception is that a stent or bypass surgery removes plaque. Stents prop open a narrowed artery, and bypass grafts route blood around a blocked section, but neither procedure eliminates the underlying disease. Plaque remains throughout the arterial tree, and new plaques can form or existing ones can rupture elsewhere. This is why patients still need cholesterol-lowering therapy and lifestyle changes after procedures. The hardware addresses one specific bottleneck; the systemic disease requires systemic treatment.

People also tend to conflate the size of a blockage with its danger, assuming that a 90% blockage is always worse than a 30% blockage. As noted earlier, the composition and stability of the plaque matter at least as much as its size. A small, inflamed, thin-capped plaque can rupture and cause a fatal heart attack, while a large calcified plaque may cause nothing more than exertional chest pain. This is why aggressive cholesterol lowering is recommended even for people whose angiograms show only moderate narrowing.

The Role of Inflammation

Cholesterol gets most of the attention, but inflammation is the other half of the atherosclerosis story. Plaque formation is fundamentally an inflammatory process. The macrophages that infiltrate the artery wall and become foam cells are immune cells responding to what they perceive as an injury.¹ The ongoing cycle of immune-cell recruitment, cell death, and debris accumulation is driven by inflammatory signaling within the artery wall.

This has led researchers to investigate whether directly targeting inflammation, independent of cholesterol, can reduce cardiovascular events. The most prominent trial in this area used an anti-inflammatory drug called canakinumab in patients who had already had a heart attack and found that reducing inflammation lowered the rate of future events even without changing cholesterol levels. The finding was a proof-of-concept moment for the field, though canakinumab itself came with side effects that limited its practical use. The broader takeaway is that controlling inflammation, through medication, exercise, weight loss, or dietary changes, is likely an important part of both preventing new plaque formation and stabilizing plaque that already exists.

For everyday purposes, this means that lifestyle factors which reduce systemic inflammation, such as regular physical activity, maintaining a healthy weight, eating a diet rich in vegetables and whole grains, and not smoking, contribute to plaque management through mechanisms that go beyond their effect on cholesterol numbers. A person who gets their LDL to target but remains sedentary, overweight, and chronically inflamed is probably not getting the full benefit of their statin prescription. The cholesterol-lowering and inflammation-reducing aspects of treatment work best in combination.